BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35496328)

  • 1. Design, synthesis,
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR
    Anwer KE; El-Hddad SSA; Abd El-Sattar NEA; El-Morsy A; Khedr F; Mohamady S; Keshek DE; Salama SA; El-Adl K; Hanafy NS
    RSC Adv; 2023 Nov; 13(50):35321-35338. PubMed ID: 38053688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, docking, ADMET and anticancer evaluations of
    Alsulaimany M; El-Adl K; Aljohani AKB; Alharbi HY; Alatawi OM; Aljohani MS; El-Morsy A; Almadani SA; Alsimaree AA; Salama SA; Keshek DE; Mohamed AA
    RSC Adv; 2023 Dec; 13(51):36301-36321. PubMed ID: 38093733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
    Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
    RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR
    El-Gaby MSA; Abdel Reheim MAM; Akrim ZSM; Naguib BH; Saleh NM; El-Adasy ABAAM; El-Adl K; Mohamady S
    Drug Dev Res; 2024 Feb; 85(1):e22143. PubMed ID: 38349267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
    Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
    Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, in silico molecular docking, and ADMET studies of quinoxaline-isoxazole-piperazine conjugates as EGFR-targeting agents.
    Ali MI; Thirukovela NS; Kumar GB; Dasari G; Badithapuram V; Manchal R; Bandari S
    Chem Biol Drug Des; 2024 Mar; 103(3):e14499. PubMed ID: 38444047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
    El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
    Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARĪ³ Agonists.
    Abdelgawad MA; El-Adl K; El-Hddad SSA; Elhady MM; Saleh NM; Khalifa MM; Khedr F; Alswah M; Nayl AA; Ghoneim MM; Abd El-Sattar NEA
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents.
    Abd El-Sattar NEA; El-Adl K; El-Hashash MA; Salama SA; Elhady MM
    Bioorg Chem; 2021 Oct; 115():105186. PubMed ID: 34314914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.